DPYD and cancer: Thus, these data demonstrated the potential role of rare genetic DPYS variants in personalizing fluoropyrimidine-based therapy, especially in cancer patients with normal DPYD activity, and further research efforts are certainly needed to translate these findings into clinical practice.